Ago ovar studien
WebObjectives: Results on the prognostic value of human epidermal growth factor receptor 2 (HER-2)/neu in ovarian cancer are inconsistent. This exploratory analysis evaluates Her-2/neu as a prognostic factor in a large cohort of patients with advanced-stage ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy within a prospective … WebNov 25, 2024 · Study Description Go to Brief Summary: This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be registered into the trial after providing a 1st written informed consent.
Ago ovar studien
Did you know?
WebResponsible Party: AGO Study Group ClinicalTrials.gov Identifier: NCT01166737 History of Changes Other Study ID Numbers: AGO-OVAR OP.4 DESKTOP III Study First Received: July 16, 2010 Last Updated: May 29, 2012 Health Authority: Germany: Ethics Commission Keywords provided by AGO Study Group: Ovarian Cancer Chemotherapy WebThe AGO Kommission Ovar already published a statement in 2013, warning about the uncritical use of hyperthermic intraperitoneal chemotherapy (HIPEC) outside controlled …
WebSep 5, 2014 · Unabhängige Analyse der AGO-OVAR 12, einer GCIG/ENGOT-Intergroup Phase III Studie mit Nintedanib in der Firstline Therapie beim Ovarialkarzinom Authors: S Mahner Felix Hilpert Krankenhaus... WebMay 1, 2006 · Die geringe mediane Überlebenszeit der GOG-172-Studie im Kontrollarm (49,7 Monate) weicht von vergleichbaren Kollektiven dreier AGO-OVAR Studien und der GOG 158 (56,5 - 59,5 Monate) ab. Wäre das...
WebFeb 8, 2024 · Im Rahmen der AGO OVAR 2.21 wurde daher diese Kombination mit Bevacizumab gegen Carboplatin/Gemcitabin/Bevacizumab geprüft. Hier zeigte sich … WebFeb 18, 2024 · AGO Research GmbH: ClinicalTrials.gov Identifier: NCT04274426 Other Study ID Numbers: AGO-OVAR 2.34 2024-004207-39 ( EudraCT Number ) First Posted: …
WebAGO-OVAR OP.7 (TRUST) Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST) ClinicalTrials.gov Identifier NCT02828618 Sponsor AGO Study Group …
WebJun 2, 2024 · AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced … the ukiah daily journal newspaperWebApr 14, 2024 · Seit 2024 gab es auf der Ebene des Gemeinsamen Bundesausschusses (G-BA) intensive Diskussionen über den Zusatznutzen dieser Arzneimittel, nachdem die initialen Zulassungsdaten „nur“ einen Unterschied im Progressionsfreien Überleben (PFS) zeigten. Inzwischen liegen Langzeitdaten von 8 randomisierten Studien vor. Ergebnisse. … sff chronsWebThe AGO Kommission Ovar already published a statement in 2013, warning about the uncritical use of hyperthermic intraperitoneal chemother-apy(HIPEC)outside controlled studies.Thisstate- ... prospektiven, kontrollierten Studien nicht zu empfehlen und abzulehnen ist. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, sffas fbwtWebLeading group: AGO Clinical Trial Study: Lion: Lymphadenectomy In Ovarian Neoplasms Final number of patients: 650 Participating groups: A-AGO, BGOG, MaNGO, MITO, … sff atx pcWebDas Qualitätssicherungsprogramm der AGO Organkommission OVAR (QS-OVAR): Versorgungsstruktur und Realität in Deutschland 2001 Analyse der Versorgungsstruktur … the uk human rights act 1998WebAGO-OVAR OP.4 (AGO DESKTOP OVAR III) A project of the AGO Study Group Ovarian Cancer (AGO-OVAR) An open-label prospectively randomized controlled multicenter-trial sff chartsff build